EDUCATION

Undergraduate Degree

  • University of Michigan , 1991 , Ann Arbor , MI

Medical School

  • Kansas City University of Medicine and Biosciences , 1999 , Kansas City , MO

Internship

Internal Medicine and Pediatrics
  • Cleveland Clinic , Cleveland , OH

Residency

Internal Medicine and Pediatrics
  • Cleveland Clinic , Cleveland , OH

Fellowship

Pulmonary Medicine
  • Boston Children's Hospital , 2006 , Boston , MA

CERTIFICATIONS

  • American Board of Internal Medicine
  • American Board of Pediatrics, General Pediatrics

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis. J Cyst Fibros. 2021 Sep 16. View abstract
  2. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis. J Cyst Fibros. 2021 Sep 13. View abstract
  3. Favorable Clinician Acceptability of Telehealth as Part of the Cystic Fibrosis Care Model during the COVID-19 Pandemic. Ann Am Thorac Soc. 2021 09; 18(9):1588-1592. View abstract
  4. Family-building and parenting considerations for people with cystic fibrosis. Pediatr Pulmonol. 2021 Aug 18. View abstract
  5. The Effects of Ivacaftor on Bone Density and Microarchitecture in Children and Adults with Cystic Fibrosis. J Clin Endocrinol Metab. 2021 03 08; 106(3):e1248-e1261. View abstract
  6. Men's health in the modern era of cystic fibrosis. J Cyst Fibros. 2020 Dec 26. View abstract
  7. Integration of mental health screening and treatment into cystic fibrosis clinics: Evaluation of initial implementation in 84 programs across the United States. Pediatr Pulmonol. 2020 11; 55(11):2995-3004. View abstract
  8. Supporting the Medically Fragile: Individualized Approach to Empowering Young Adults With Chronic Disease During the COVID-19 Pandemic. J Adolesc Health. 2020 09; 67(3):453-455. View abstract
  9. Children's Hospitals Caring for Adults During a Pandemic: Pragmatic Considerations and Approaches. J Hosp Med. 2020 05; 15(5):311-313. View abstract
  10. Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study. Lancet Respir Med. 2019 12; 7(12):1027-1038. View abstract
  11. Antifibrinolytic Agents for Hemoptysis Management in Adults With Cystic Fibrosis. Chest. 2019 06; 155(6):1226-1233. View abstract
  12. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 10 25; 379(17):1599-1611. View abstract
  13. Sexual and Reproductive Health of Young Women With Cystic Fibrosis: A Concept Mapping Study. Acad Pediatr. 2019 04; 19(3):307-314. View abstract
  14. A Pilot Study of Inspiratory Muscle Training to Improve Exercise Capacity in Patients with Fontan Physiology. Semin Thorac Cardiovasc Surg. 2018 Winter; 30(4):462-469. View abstract
  15. Overcoming barriers to a successful transition from pediatric to adult care. Pediatr Pulmonol. 2017 Nov; 52(S48):S52-S60. View abstract
  16. Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation. Clin Transl Gastroenterol. 2017 Mar 16; 8(3):e81. View abstract
  17. Comparison of Nasal Potential Difference and Intestinal Current Measurements as Surrogate Markers for CFTR Function. J Pediatr Gastroenterol Nutr. 2016 11; 63(5):e92-e97. View abstract
  18. Young adults with cystic fibrosis have altered trabecular microstructure by ITS-based morphological analysis. Osteoporos Int. 2016 08; 27(8):2497-505. View abstract
  19. Risk Factors for Hearing Loss in Patients with Cystic Fibrosis. J Am Acad Audiol. 2016 01; 27(1):6-12. View abstract
  20. Correlations of salivary biomarkers with clinical assessments in patients with cystic fibrosis. PLoS One. 2015; 10(8):e0135237. View abstract
  21. Trends in bone mineral density in young adults with cystic fibrosis over a 15 year period. J Cyst Fibros. 2015 Jul; 14(4):526-32. View abstract
  22. Compromised bone microarchitecture and estimated bone strength in young adults with cystic fibrosis. J Clin Endocrinol Metab. 2014 Sep; 99(9):3399-407. View abstract
  23. An automated integrated platform for rapid and sensitive multiplexed protein profiling using human saliva samples. Lab Chip. 2014 Mar 21; 14(6):1087-98. View abstract
  24. Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis. J Cyst Fibros. 2013 Jan; 12(1):54-9. View abstract
  25. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010 Nov 18; 363(21):1991-2003. View abstract
  26. Employment experiences among adolescents and young adults with cystic fibrosis. Disabil Rehabil. 2011; 33(11):922-6. View abstract
  27. A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity. J Cyst Fibros. 2009 Dec; 8(6):418-24. View abstract
  28. Sensorineural hearing loss in patients with cystic fibrosis. Otolaryngol Head Neck Surg. 2009 Jul; 141(1):86-90. View abstract
  29. Recovery of Herbaspirillum species from persons with cystic fibrosis. J Clin Microbiol. 2008 Aug; 46(8):2774-7. View abstract
  30. Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis. Trends Mol Med. 2008 Mar; 14(3):120-33. View abstract
  31. Polymerase chain reaction/denaturing gradient gel electrophoresis (PCR/DGGE): sensitivity, band pattern analysis, and methodologic optimization. Am J Dermatopathol. 1999 Dec; 21(6):547-51. View abstract
  32. High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model. J Pharmacol Exp Ther. 1997 Feb; 280(2):576-83. View abstract
  33. 5-Hydroxytryptamine2A (5-HT2A) receptor desensitization can occur without down-regulation. J Pharmacol Exp Ther. 1995 Dec; 275(3):1638-46. View abstract
  34. Lymphomatoid papulosis and associated cutaneous lymphoproliferative disorders exhibit a common clonal origin. J Invest Dermatol. 1995 Jul; 105(1):51-5. View abstract
  35. Differential ergoline and ergopeptine binding to 5-hydroxytryptamine2A receptors: ergolines require an aromatic residue at position 340 for high affinity binding. Mol Pharmacol. 1995 Mar; 47(3):450-7. View abstract
  36. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar; 268(3):1403-10. View abstract